(Q34737119)

English

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib (English)

1 reference

Europe PubMed Central

4 August 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

K N Ganjoo

1

1 reference

Europe PubMed Central

4 August 2017

V M Villalobos

2

1 reference

Europe PubMed Central

4 August 2017

A Kamaya

3

1 reference

Europe PubMed Central

4 August 2017

G A Fisher

4

1 reference

Europe PubMed Central

4 August 2017

J E Butrynski

5

1 reference

Europe PubMed Central

4 August 2017

J A Morgan

6

1 reference

Europe PubMed Central

4 August 2017

A J Wagner

7

1 reference

Europe PubMed Central

4 August 2017

D D'Adamo

8

1 reference

Europe PubMed Central

4 August 2017

A McMillan

9

1 reference

Europe PubMed Central

4 August 2017

G D Demetri

10

1 reference

Europe PubMed Central

4 August 2017

S George

11

1 reference

Europe PubMed Central

4 August 2017

publication date

1 January 2014

1 reference

Europe PubMed Central

4 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

4 August 2017

25

1 reference

Europe PubMed Central

4 August 2017

1

1 reference

Europe PubMed Central

4 August 2017

236-240

1 reference

Europe PubMed Central

4 August 2017

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4271129

7 July 2018

Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4271129

7 July 2018

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4271129

7 July 2018

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4271129

7 July 2018

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4271129

7 July 2018

Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4271129

7 July 2018

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT484

21 January 2018

Serum vascular endothelial growth factor and angiogenesis are related to the prognosis of patients with gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT484

21 January 2018

Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT484

21 January 2018

Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4271129

26 October 2018

Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach

1 reference

https://pubmed.ncbi.nlm.nih.gov/24356634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoxia-inducible factor-1alpha is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor

1 reference

https://pubmed.ncbi.nlm.nih.gov/24356634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDT484

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34737119&oldid=1584536731"